| Primary |
| Colon Cancer Metastatic |
16.7% |
| Hepatic Neoplasm Malignant |
13.3% |
| Colorectal Cancer Metastatic |
10.0% |
| Ovarian Cancer Metastatic |
10.0% |
| Colon Cancer |
6.7% |
| Mesothelioma |
6.7% |
| Multiple Myeloma |
6.7% |
| Neuroendocrine Tumour |
6.7% |
| Pancreatic Carcinoma Metastatic |
6.7% |
| Rectal Cancer Metastatic |
6.7% |
| Endometrial Cancer Metastatic |
3.3% |
| Gallbladder Cancer Metastatic |
3.3% |
| Leiomyosarcoma |
3.3% |
|
| Renal Failure Acute |
8.0% |
| Small Intestinal Obstruction |
8.0% |
| Thrombocytopenia |
8.0% |
| Vomiting |
8.0% |
| Wheezing |
8.0% |
| Blood Bilirubin Increased |
4.0% |
| Colitis |
4.0% |
| Disease Progression |
4.0% |
| Dysphagia |
4.0% |
| Eastern Cooperative Oncology Group Performance Status Worsened |
4.0% |
| Hyperglycaemia |
4.0% |
| Hypoxia |
4.0% |
| International Normalised Ratio Increased |
4.0% |
| Intra-abdominal Haematoma |
4.0% |
| Musculoskeletal Chest Pain |
4.0% |
| Oxygen Saturation Decreased |
4.0% |
| Pain |
4.0% |
| Pericardial Effusion |
4.0% |
| Pleural Effusion |
4.0% |
| Pneumonia |
4.0% |
|
| Secondary |
| Plasma Cell Myeloma |
41.3% |
| Infection Prophylaxis |
19.7% |
| Renal Transplant |
6.2% |
| Immunosuppressant Drug Therapy |
4.9% |
| Immunosuppression |
4.7% |
| Chemotherapy |
3.7% |
| Product Used For Unknown Indication |
3.1% |
| Diabetes Mellitus |
2.5% |
| Hypertension |
1.8% |
| Heart Transplant |
1.6% |
| Liver Transplant |
1.4% |
| Mucoepidermoid Carcinoma |
1.2% |
| Non-small Cell Lung Cancer |
1.2% |
| Oesophageal Carcinoma |
1.2% |
| Prophylaxis Against Graft Versus Host Disease |
1.2% |
| Multiple Myeloma |
1.0% |
| Hepatic Neoplasm Malignant |
0.8% |
| Lung Neoplasm Malignant |
0.8% |
| Lung Transplant |
0.8% |
| Acute Graft Versus Host Disease |
0.6% |
|
| Thrombotic Microangiopathy |
10.9% |
| Neutropenia |
8.7% |
| Death |
6.5% |
| Microangiopathy |
6.5% |
| Off Label Use |
6.5% |
| Surgery |
6.5% |
| Atrial Fibrillation |
4.3% |
| Confusional State |
4.3% |
| Haemorrhage |
4.3% |
| Liver Transplant Rejection |
4.3% |
| Neutropenic Infection |
4.3% |
| Pulmonary Artery Thrombosis |
4.3% |
| Renal Failure |
4.3% |
| Staphylococcal Infection |
4.3% |
| Subclavian Vein Thrombosis |
4.3% |
| Thrombocytopenia |
4.3% |
| Transplant Rejection |
4.3% |
| Acute Respiratory Distress Syndrome |
2.2% |
| Arthropathy |
2.2% |
| Biliary Sepsis |
2.2% |
|
| Concomitant |
| Product Used For Unknown Indication |
16.5% |
| Drug Use For Unknown Indication |
15.9% |
| Premedication |
10.2% |
| Immunosuppression |
8.5% |
| Renal Transplant |
8.0% |
| Prophylaxis |
5.7% |
| Liver Transplant |
4.0% |
| Chronic Graft Versus Host Disease |
3.4% |
| Kidney Transplant Rejection |
3.4% |
| Angiogram |
2.8% |
| Hepatitis C |
2.8% |
| Nuclear Magnetic Resonance Imaging |
2.8% |
| Colitis |
2.3% |
| Heart Transplant |
2.3% |
| Prophylaxis Against Transplant Rejection |
2.3% |
| Squamous Cell Carcinoma |
2.3% |
| Anaemia |
1.7% |
| Atrial Fibrillation |
1.7% |
| Blood Pressure Increased |
1.7% |
| Dyspepsia |
1.7% |
|
| White Blood Cell Count Decreased |
12.5% |
| Abortion Spontaneous |
6.3% |
| Embolism |
6.3% |
| Erythema Infectiosum |
6.3% |
| Liver Transplant Rejection |
6.3% |
| Lymphoproliferative Disorder |
6.3% |
| Myocardial Infarction |
6.3% |
| Pyrexia |
6.3% |
| Serum Sickness |
6.3% |
| Vanishing Bile Duct Syndrome |
6.3% |
| Complications Of Bone Marrow Transplant |
3.1% |
| Cough |
3.1% |
| Diarrhoea |
3.1% |
| Dizziness |
3.1% |
| Drug Ineffective |
3.1% |
| Extremity Contracture |
3.1% |
| Haemodialysis |
3.1% |
| Hypomagnesaemia |
3.1% |
| Immunosuppressant Drug Level Decreased |
3.1% |
| Infertility |
3.1% |
|
| Interacting |
|
| Rhabdomyolysis |
50.0% |
| Ventricular Fibrillation |
50.0% |
|
